JP2010513392A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010513392A5 JP2010513392A5 JP2009542031A JP2009542031A JP2010513392A5 JP 2010513392 A5 JP2010513392 A5 JP 2010513392A5 JP 2009542031 A JP2009542031 A JP 2009542031A JP 2009542031 A JP2009542031 A JP 2009542031A JP 2010513392 A5 JP2010513392 A5 JP 2010513392A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- chromen
- pain
- group
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- -1 chromen-2-one-yl group Chemical group 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 13
- 208000002193 Pain Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 206010013654 Drug abuse Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 208000019906 panic disease Diseases 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 208000011117 substance-related disease Diseases 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 206010033664 Panic attack Diseases 0.000 claims 2
- 206010041250 Social phobia Diseases 0.000 claims 2
- 206010043269 Tension headache Diseases 0.000 claims 2
- 208000008548 Tension-Type Headache Diseases 0.000 claims 2
- 206010043903 Tobacco abuse Diseases 0.000 claims 2
- 206010046543 Urinary incontinence Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 230000001561 neurotransmitter reuptake Effects 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000036640 Asperger disease Diseases 0.000 claims 1
- 201000006062 Asperger syndrome Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 claims 1
- 208000026097 Factitious disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000008705 Nocturnal Myoclonus Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 206010052794 Panic disorder with agoraphobia Diseases 0.000 claims 1
- 206010033668 Panic disorder without agoraphobia Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 208000012202 Pervasive developmental disease Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 206010070606 Post stroke depression Diseases 0.000 claims 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 206010052276 Pseudodementia Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 208000036353 Rett disease Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims 1
- 208000013200 Stress disease Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 208000011962 Substance-induced mood disease Diseases 0.000 claims 1
- 231100000395 Substance-induced mood disorder Toxicity 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 206010001584 alcohol abuse Diseases 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 208000025746 alcohol use disease Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 208000025748 atypical depressive disease Diseases 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000022257 bipolar II disease Diseases 0.000 claims 1
- 208000022266 body dysmorphic disease Diseases 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000037326 chronic stress Effects 0.000 claims 1
- 201000001272 cocaine abuse Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 125000005059 halophenyl group Chemical group 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 230000000938 luteal effect Effects 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 230000007074 memory dysfunction Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 230000000422 nocturnal effect Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000023515 periodic limb movement disease Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 206010036596 premature ejaculation Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 201000001716 specific phobia Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000002889 sympathetic effect Effects 0.000 claims 1
- 208000016686 tic disease Diseases 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 206010046494 urge incontinence Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87580506P | 2006-12-20 | 2006-12-20 | |
| DKPA200601679 | 2006-12-20 | ||
| PCT/EP2007/064131 WO2008074798A1 (en) | 2006-12-20 | 2007-12-18 | Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010513392A JP2010513392A (ja) | 2010-04-30 |
| JP2010513392A5 true JP2010513392A5 (enExample) | 2011-01-27 |
Family
ID=39289568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009542031A Abandoned JP2010513392A (ja) | 2006-12-20 | 2007-12-18 | 新規クロメン−２−オン誘導体及びモノアミン神経伝達物質再取り込み阻害薬としてのそれらの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20090312364A1 (enExample) |
| EP (1) | EP2121678B1 (enExample) |
| JP (1) | JP2010513392A (enExample) |
| AU (1) | AU2007336291A1 (enExample) |
| CA (1) | CA2673454A1 (enExample) |
| MX (1) | MX2009005916A (enExample) |
| WO (1) | WO2008074798A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200800980A (en) | 2006-02-17 | 2008-01-01 | Neurosearch As | Novel compounds |
| EP2121677B1 (en) | 2006-12-20 | 2010-11-03 | NeuroSearch A/S | Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| TW200904815A (en) | 2007-05-09 | 2009-02-01 | Neurosearch As | Novel compounds |
| MX2011011904A (es) | 2009-05-15 | 2011-12-08 | Neurosearch As | Derivados de cromen-2-ona y su uso como inhibidores de la reabsorcion del neurotransmisor de monoamina. |
| US20130040985A1 (en) | 2010-01-29 | 2013-02-14 | Neurosearch A/S | Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| CN104244944B (zh) * | 2011-12-30 | 2018-06-08 | Ptc医疗公司 | 用于治疗脊髓性肌萎缩症的化合物 |
| MA45276A (fr) * | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
| EP4241839A3 (en) * | 2019-08-06 | 2023-11-15 | Initiator Pharma A/S | Compound for combination treatment |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003106452A2 (en) * | 2002-06-12 | 2003-12-24 | Millennium Pharmaceuticals, Inc. | Antagonists of melanin concentrating hormone receptor |
| EP1797088B1 (en) * | 2004-09-30 | 2011-01-05 | NeuroSearch A/S | Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| MX2007002384A (es) * | 2004-09-30 | 2007-05-11 | Neurosearch As | Nuevos derivados de cromen-2-ona y su uso como inhibidores de la reabsorcion del neurotransmisor de monoamina. |
| CA2591621A1 (en) * | 2004-12-17 | 2006-06-22 | Neurosearch A/S | Enantiomers of 3-heteroaryl-8h-8-azabicyclo(3.2.1)oct-2-ene and their use as monoamine neurotransmitter re-uptake inhibitors |
| TW200800980A (en) * | 2006-02-17 | 2008-01-01 | Neurosearch As | Novel compounds |
| BRPI0917802A2 (pt) * | 2008-08-21 | 2016-03-01 | Neurosearch As | método para tratar um distúrbio de ansiedade, composição farmacêutica, uso do composto, uso de uma combinação, kit de partes, método para tratar, prevenir ou aliviar um distúrbio de ansiedade de um corpo de animal vivo, e, combinação |
-
2007
- 2007-12-18 EP EP07866292A patent/EP2121678B1/en not_active Not-in-force
- 2007-12-18 JP JP2009542031A patent/JP2010513392A/ja not_active Abandoned
- 2007-12-18 US US12/520,239 patent/US20090312364A1/en not_active Abandoned
- 2007-12-18 AU AU2007336291A patent/AU2007336291A1/en not_active Abandoned
- 2007-12-18 CA CA002673454A patent/CA2673454A1/en not_active Abandoned
- 2007-12-18 MX MX2009005916A patent/MX2009005916A/es not_active Application Discontinuation
- 2007-12-18 WO PCT/EP2007/064131 patent/WO2008074798A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010513392A5 (enExample) | ||
| RU2018130727A (ru) | Органические соединения | |
| RU2007106970A (ru) | Новые хромен-2-оновые производные и их применение в качестве ингибиторов обратного захвата моноаминовых нейромедиаторов | |
| JP2009526816A5 (enExample) | ||
| RU2005138591A (ru) | Новые производные 8-аза-бицикло{3.2.1}октана и их применение в качестве ингибиторов обратного захвата моноаминовых нейротрансмиттеров | |
| JP2010513391A5 (enExample) | ||
| RU2008129865A (ru) | Новые производные хромен-2-она и их применение в качестве ингибиторов обратного захвата нейромедиаторов моноаминов | |
| MX2009005509A (es) | 2-aminoquinolina como los antagonistas de los receptores 5-hidroxitriptamina 5a (5-ht5a). | |
| JP2008524161A5 (enExample) | ||
| JPWO2019183341A5 (enExample) | ||
| JP2006517567A5 (enExample) | ||
| JP2008502651A5 (enExample) | ||
| RU2010114662A (ru) | Новые производные 1,4-диазабицикло(3.2.2)нонилпиримидина и их медицинское применение | |
| JP2006517568A5 (enExample) | ||
| JP2009526023A5 (enExample) | ||
| JP2008526923A5 (enExample) | ||
| RU2009119919A (ru) | Новые производные хромен-2-она и их применение в качестве ингибиторов обратного захвата нейромедиаторов моноаминов | |
| JPWO2020132474A5 (enExample) | ||
| JP2006507363A5 (enExample) | ||
| JP2008502650A5 (enExample) | ||
| JP2009515850A5 (enExample) | ||
| JP2008534650A5 (enExample) | ||
| JP2011511031A (ja) | 新規な９−アザ−ビシクロ［３．３．１］ノン−３−イルオキシクロメン−２−オン誘導体及びモノアミン神経伝達物質再取り込み阻害薬としてのそれらの使用 | |
| JP2010501624A5 (enExample) | ||
| JP2008534653A5 (enExample) |